Jessica Brown

Jessica Brown

Auto-generated profile, based on publicly available information

Jessica Brown

Clinical Nutrition and Lactation Children's Hospital of Orange County (CHOC) Orange California USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Menopause
Verified
Journal Article
Open access
MMMay E. Montasser
May E. Montasser
AZAyelet Ziv-Gal
Ayelet Ziv-Gal
JBJessica P. Brown
Jessica P. Brown
Jodi FlawsJodi Flaws
Jodi Flaws
IMIstvan Merchenthaler
Istvan Merchenthaler
Objective An increase in the use of selective serotonin reuptake inhibitors (SSRIs) and/or serotonin-norepinephrine reuptake inhibitors (SNRIs) to relieve menopausal hot flashes (HFs) has been observed recently. However, response to them has been heterogeneous. We hypothesized that this heterogeneity might be partially attributed to genetic variations in genes encoding the serotonin and/or norepinephrine transporters (SLC6A4 and SLC6A2). As a first step in testing the role of genetics in response to SSRIs/SNRIs, we examined the association between HFs and genetic variants within these two genes. Methods We tested 29 haplotype-tagging single nucleotide polymorphisms within SLC6A4 and SLC6A2 for their association with HFs separately for European-American (396 cases and 392 controls) and African-American (125 cases and 81 controls) premenopausal and perimenopausal women. Results We found that the minor allele of SLC6A4_rs11080121 was associated with protection against HFs (odds ratio, 0.75; 95% CI, 0.60-0.94) only in European-American women. Bioinformatics analyses indicated that rs11080121 is fully correlated with rs1042173 in the 3′ untranslated region of SLC6A4. The minor allele of rs1042173 seems to disrupt a conserved binding site for hsa-miR-590-3p microRNA. Conclusions Disruption of a microRNA binding site leads to higher expression of SLC6A4, higher expression of SLC6A4 leads to depletion of serotonin in synaptic clefts, and depletion of serotonin triggers the presynaptic autoreceptor feedback mechanism to produce more serotonin, which is protective against HFs. This is the first study to test the association between HFs in both European-American and African-American premenopausal and perimenopausal women and genetic variants in two neurotransmitter transporter genes, SLC6A2 and SLC6A4. This information can be used in tailoring the pharmaceutical use of SSRIs/SNRIs for HF relief.

1 July 2020 in Surgery Open Science
Verified
Journal Article
Open access
RCR. Gregory Conway
R. Gregory Conway
NONatalie O'NEill
Natalie O'NEill
JBJessica Brown
Jessica Brown
SKStephen Kavic
Stephen Kavic
Estimating distance is a common task in surgery, yet development of distance estimation ability receives little attention in surgical training. Although the Small bites versus large bites for closure of abdominal midline incisions (STITCH) trial reinforced the importance of suture spacing by demonstrating reduced incisional hernia incidence in placement of 5-mm fascial sutures over 1 cm, we hypothesize that neither trainee nor attending surgeons possess the ability to estimate these distances with accuracy. We distributed a 4-question distance estimation exercise and a 6-question survey to resident and attending surgeons at a single academic medical center. The mean and the absolute error were compared using a t test. Most participants were trainees (44 vs 16 attendings, N = 60), and 27% used the metric system prior to undergraduate studies. The mean absolute errors for 5-mm and 1-cm mark placement were 1.40 and 2.07 mm, respectively. The 5-mm mark placement estimates ranged from 2.01 to 11.69 mm, and the 1-cm estimates ranged from 4.82 to 19.19 mm. There was no statistically significant difference in the estimates or absolute errors between trainees and attendings (5 mm P = .202; 1 cm P = .302). These findings suggest that estimation of distance is a challenge, and development of this fundamental skill during surgical training may have important clinical consequences.

16 May 2022 in Journal of the Academy of Nutrition and Dietetics
Verified
Journal Article
Closed access
JLJessica Lowe
Jessica Lowe
JBJessica Brown
Jessica Brown
KKKatie Klier
Katie Klier
JWJennifer Doll White
Jennifer Doll White
LALucia Briceno Alliegro
Lucia Briceno Alliegro
DMDanine Mele-Hayes
Danine Mele-Hayes

10 June 2025 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
JBJessica Brown
Jessica Brown
SBShonda Brown
Shonda Brown
KCKelsey Childs
Kelsey Childs
RARicardo Aguilar
Ricardo Aguilar

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
EHElizabeth Halvorsen
Elizabeth Halvorsen
MVMarin Vulić
Marin Vulić
KBKelsey Barrasso
Kelsey Barrasso
NBNicholas Beauchemin
Nicholas Beauchemin
JBJessica Brown
Jessica Brown
MHMatthew Henn
Matthew Henn
In chronic liver disease (CLD), gut microbiome disruption worsens with disease severity and growing evidence suggests it is a key driver of infection risk through a combination of intestinal pathogen expansion from a loss of colonization resistance and dysfunction of the gastrointestinal (GI) barrier. For the SER-147 preclinical program, we evaluated rationally designed cultivated consortia of human commensal bacteria in vitro and in vivo for the ability to reduce the abundance of pathogens commonly observed in patients with CLD, such as Enterococcus and Enterobacteriaceae. Candidate consortia for SER-147 were designed by leveraging genomic data from public observational CLD patient studies and Seres interventional human trial data to include taxa associated with reduced risk of infection and select strains from Seres’ strain library to maximize features associated with decolonizing key pathogens. We developed a novel in vitro gut-ecology model (iGEM) system that propagates human stool-derived microbial communities to evaluate candidate consortia for their ability to reduce titers of vancomycin-resistant Enterococcus faecium (VRE), and both carbapenem-resistant Klebsiella pneumoniae (CR-Kpn) and Escherichia coli (CR-Ec). In vivo, candidate consortia were evaluated for their ability to reduce fecal titers of VRE and CR-Kpn in mouse models of gut pathogen colonization. Reduction in abundance of Cr-Kpn, Cr-Ec, and VRE after microbiome intervention in the iGEM system. Reduction in abundance of Cr-Kpn and VRE after microbiome intervention in mouse models of gut pathogen colonization. (A) Wild-type C57BL/6 mice underwent antibiotic conditioning prior to pathogen challenge. Following the introduction of pathogen (Day 0) mice were dosed daily vial oral gavage with five unique candidate consortia (DE061, DE456, DE240, DE714, and DE492) as the microbiome intervention or vehicle only for 6 days and fecal titers are monitored for a 3-week period to evaluate pathogen abundance (B,C) The titers of VRE or CR-Kpn were quantified in fecal pellets by plating on selective agar at the indicated time-points. The median (B) CR-Kpn and (C) VRE CFU per gram of feces was calculated for each group and plotted on the line graph (n=9 per group). L.O.D., limit of detection. Preclinical assessments in vitro and in vivo support the ability of SER-147 candidate consortia to reduce VRE, CR-Kpn, and CR-Ec abundance in the gut. These results support the potential ability of microbiome therapeutics to reduce the risk of infection in patients with CLD. Elizabeth Halvorsen, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Marin Vulić, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Kelsey Barrasso, PhD, Seres Therapeutics: Stocks/Bonds Nicholas Beauchemin, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Jessica Brown, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Nathaniel J. Ennis, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Melissa Mayol, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Jenna Wurster, PhD, Seres Therapeutics: Paid Employee|Seres Therapeutics: Stocks/Bonds Edward J. O'Brien, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Christopher Ford, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Matthew Henn, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JWJenna Wurster
Jenna Wurster
TSTim Straub
Tim Straub
EOEdward J O’bRien
Edward J O’bRien
NENathaniel J Ennis
Nathaniel J Ennis
MMMelissa Mayol
Melissa Mayol
MHMatthew Henn
Matthew Henn
Chronic liver disease (CLD) is a major cause of morbidity and mortality, with high risk of infection as CLD progresses. Gut microbiome disruption, which worsens with CLD severity, causes loss of colonization resistance and impaired gastrointestinal (GI) barrier function, enabling pathogen translocation across the GI tract. We evaluated shotgun metagenomic data from 3 studies and 288 patients with CLD to evaluate the role of the microbiome in the progression of disease, and enable the rational design of SER-147, a cultivated consortium of human commensal bacteria, to restore colonization resistance against key pathogens and promote GI homeostasis in CLD patients. Public observational studies of patients with CLD used to evaluate the role of the microbiome in CLD progression. Reverse Translational Design Pipeline for SER-147 Candidate Consortia. The design framework for preclinical drug candidates integrates a combination of public observational datasets in CLD patients, Seres interventional clinical trials, and proprietary bioinformatic algorithms to inform disease target identification. These data are subsequently fed into a rational design framework that utilizes (1) trial engraftment, (2) disease-informed preclinical microbiome modeling, and (3) functional learnings from SSL to identify taxa with the desired pharmacological properties. Selection of strains by baseline characteristics for use in SER-147. Nineteen candidate bacterial strains were selected for inclusion in SER-147 candidate consortia based on numerous genotypic and phenotypic traits. Evidence of engraftment of strains in Seres clinical trials was a minimum inclusion criterion to help ensure pharmacokinetic capability of SER-147. Genomic and in silico design features included: depletion during CLD progression, predicted lantibiotic production, presence of KEGG-Orthologs for oxygen tolerance, and predicted contribution to decolonization phenotypes based on preclinical modeling. Phenotypic design features were selected based on extensive in vitro and in vivo characterization of strains and include the generation of barrier-restorative metabolites like short-chain fatty acids (SCFA), secondary bile acid conversion, and tryptophan metabolism. SER-147 candidate strains were additionally assessed in vitro for their capacity to tolerate low pH, grow in hypoxic culture conditions, suppress IL-8 activity, and utilize lactulose as a sole carbon source as it is a commonly prescribed medication in the CLD patient population Patients with CLD are at increased risk of mortality from infections seeded from the GI tract due to microbiome disruption and GI barrier compromise. Microbiome therapeutics such as SER-147 represent a potentially powerful and novel approach to reducing the risk of infection in CLD by directly targeting key risk factors of GI-seeded infections. Jenna Wurster, PhD, Seres Therapeutics: Paid Employee|Seres Therapeutics: Stocks/Bonds Tim Straub, MS, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Edward J. O'Brien, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Nathaniel J. Ennis, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Melissa Mayol, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Jessica Brown, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Marin Vulić, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Nicholas Beauchemin, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Elizabeth Halvorsen, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Christopher Ford, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Matthew Henn, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds